Gastric Cancer
Conditions
Interventions
Dual Tracer Group:ICG+Carbon Nanoparticles
Single Tracer Group (ICG):Single Tracer
Single Tracer Group (Carbon Nanoparticles):Carbon Nanoparticles
No Tracer Group:None
Sponsors
Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School Nanjing University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age: 18-75 years old; 2. Pathologically confirmed primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring, undifferentiated adenocarcinoma) by gastroscopic biopsy; 3. According to the seventh edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, the preoperative assessment clinical stage is T1-4a (cT1-4a), N-/+, M0; 4. No distant metastasis, no direct invasion of adjacent organs such as pancreas and spleen in preoperative examination; 5. The ECGO score is 0 or 1, and the ASA grade is I-III; 6. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women; 2. Suffering from serious mental illness; 3. Previous history of upper abdominal surgery (except laparoscopic cholecystectomy); 4. History of gastric surgery (including ESD and EMR); 5. Those who refuse laparoscopic surgery; 6. Those who have a history of allergy to iodine contrast agents in the past; 7. Those with regional lymph node enlargement more than 3cm found by preoperative imaging; Those with a history of other malignant tumors within 8.5 years; 9. Neoadjuvant chemoradiotherapy before surgery; 10. Patients with unstable angina or myocardial infarction within the past six months; 11. Patients who continuously use hormones systemically within one month; 12. Combined with other surgeries; 13. Emergency surgery due to complications (bleeding, perforation, obstruction) caused by gastric cancer; 14. FEV1 is less than 50% of the predicted value.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total number of retrieved lymph node; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive rate of metastic lymph node;Total number of metastic lymph node;3-year overall survival;3-year progression-free survival;3-year disease-free survival rate; | — |
Countries
China
Contacts
Public ContactGuan Wenxian
Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School Nanjing University
Outcome results
None listed